Authorship for sale: Some journals willing to add authors to papers they didn’t write

Got $300? Then you can be added as an author to a paper — even if you had no role in the research.

That’s right — some journals are willing to add authors to papers they didn’t write, often for a fee. This realization comes from one of the many sting experiments we’ve witnessed over the years, designed to expose the perils of the publishing industry, in which some journals will claim to peer review and publish any manuscript for a fee — no matter how nonsensical the content. Pravin Bolshete, a medical writer and researcher from India, wanted to explore a different side of predatory publishing — would journals agree to add a fictional author to a manuscript he/she didn’t write?

Presenting his findings at the Eighth Peer Review Congress this week in Chicago, Bolshete reported that, after sending hundreds of emails to publishers considered predatory according to the now-defunct (and controversial) list compiled by librarian Jeffrey Beall, 16% agreed to add an author to a paper.

Bolshete told us:

Continue reading Authorship for sale: Some journals willing to add authors to papers they didn’t write

Carlo Croce, Ohio State researcher facing misconduct allegations, suing New York Times for defamation

Carlo Croce

Carlo Croce, a cancer researcher at The Ohio State University who has faced numerous allegations of research misconduct, has filed a lawsuit against the New York Times, claiming the newspaper defamed him in a March 8 story.

Croce filed the civil suit May 10, in the US District Court for the Southern District of Ohio, naming as co-defendants Times reporters James Glanz and Agustin Armendariz, publisher Arthur Sulzberger, Jr., and executive editor Dean Baquet. According to court documents, he’s seeking damages in excess of $75,000. The Times lawsuit was first reported by Courthouse News in May, but it’s actually the second defamation suit Croce filed that we know of.

In April, we’ve recently learned, Croce filed a separate defamation lawsuit against David Sanders, a professor at Purdue University and a key source for the Times story. Croce is seeking damages from Sanders in excess of $75,000.

Croce’s lawyer, Thomas Hill, of Columbus, Ohio firm Kegler Brown Hill + Ritter, told Retraction Watch his client was fighting a “David and Goliath battle” against the Times: Continue reading Carlo Croce, Ohio State researcher facing misconduct allegations, suing New York Times for defamation

UCSF, VA investigations find “clear evidence” of misconduct in cancer papers

Earlier this year, the University of California, San Francisco and the San Francisco Veterans Administration Medical Center teamed up to write a letter.

Addressed to the editorial office at the American Association of Cancer Research (AACR), the letter, parts of which have been published in a retraction notice, contained information concerning two papers on genetic risk factors for a type of kidney cancer and a type of uterine cancer, respectively, published in different AACR journals over a decade ago by researchers affiliated with the institutions.

The papers had been at the center of research misconduct investigations at both UCSF and the VA and the investigations came to the conclusion that both papers contained:

fabrication or falsification of data that constitutes Research Misconduct.

Though one of the papers has been retracted, it’s unclear what will happen to the other. [Note: See update at the bottom of the post.] Continue reading UCSF, VA investigations find “clear evidence” of misconduct in cancer papers

Predatory journals: Not just a problem in developing world countries, says new Nature paper

David Moher

“Common wisdom,” according to the authors of a new piece in Nature, “assumes that the hazard of predatory publishing is restricted mainly to the developing world.” But the authors of the new paper, led by David Moher of the Ottawa Hospital Research Institute, found that more than half — 57% — of the 2,000 articles published in journals they determined were predatory were from high-income countries. In fact, the U.S. was second only to India in number of articles published in such journals. We asked Moher, who founded Ottawa Hospital’s Centre for Journalology in 2015, a few questions about the new work.

Retraction Watch (RW): Your paper comes out on the heels of a Bloomberg story showing that Big Pharma researchers are also publishing in predatory journals. Does all of this suggest that our understanding of who publishes in predatory journals is incomplete, or even wrong? Continue reading Predatory journals: Not just a problem in developing world countries, says new Nature paper

Data fabrication by ex-Harvard researcher takes down paper on Huntington’s disease

A researcher at Harvard Medical School and Massachusetts General Hospital is retracting a paper due to “inappropriate manipulation and fabrication of data” by the first author.

According to the retraction notice, published Aug. 22, corresponding author Marian DiFiglia is retracting the paper because the alleged misconduct by the first author, Antonio Valencia:

led to an incorrect conclusion in the paper that NADPH activity is elevated in Huntington’s disease (HD). Some original data were missing and efforts to replicate findings using the reported method or an alternative approach were unsuccessful. An institutional faculty panel supports the decision and the reasons for the retraction.

The notice added that the alleged data manipulation and fabrication affected bar graphs in two of the paper’s figures.

Terri Ogan, a spokesperson for Mass General, told Retraction Watch that Valencia no longer works at the institution, but declined to say whether there has been an investigation into the alleged misconduct: Continue reading Data fabrication by ex-Harvard researcher takes down paper on Huntington’s disease

Amid legal battle, psych journal issuing caution about torture paper

A psychology journal plans to issue an editor’s note about a controversial paper exploring what the author called “the biggest scandal to hit” the American Psychological Association (APA) in years.

The note cautions readers that the subject of the paper, published in the SAGE journal Teaching of Psychology, is part of a pending lawsuit, and that “teachers considering using the article in their classrooms” should watch for developments in the case.   Continue reading Amid legal battle, psych journal issuing caution about torture paper

PNAS retracts paper linked to ex-Ohio State researcher who had chemistry PhD revoked

Researchers from The Ohio State University and The Scripps Research Institute are retracting a 2013 paper in Proceedings of the National Academy of Sciences after they uncovered data irregularities.

The retraction notice for “Somatic hypermutation maintains antibody thermodynamic stability during affinity maturation,” will appear online on Sept. 5. The paper purported to find clues about what makes antibodies stable at different temperatures. In a press release issued at the time of publication, corresponding author Thomas Magliery, of The Ohio State University, said the paper might help pharmaceutical companies make better antibody-based drugs. It has been cited 36 times, according to Clarivate Analytics’ Web of Science.

At some point — we’re not exactly sure when — the authors discovered that the antibody stability data was suspect. According to the notice: Continue reading PNAS retracts paper linked to ex-Ohio State researcher who had chemistry PhD revoked

Carlo Croce, OSU cancer researcher under investigation, retracts paper

Carlo Croce

A researcher whose work has come under repeated scrutiny has retracted a 2008 paper for “errors that occurred in the construction” of various figures.

Carlo Croce, the corresponding author of the newly retracted paper, has been dogged by misconduct accusations for years — as recently described in the New York Times. His employer, The Ohio State University, has recently re-opened an investigation into his work. Seven of his papers have now been retracted, and fourteen have been corrected for image and text issues such as manipulation, duplication, and errors, as well as two others earning expressions of concern.

Here’s the retraction notice for “Fhit Interaction with Ferredoxin Reductase Triggers Generation of Reactive Oxygen Species and Apoptosis of Cancer Cells,” in the Journal of Biological Chemistry: Continue reading Carlo Croce, OSU cancer researcher under investigation, retracts paper

When is a citation not enough?

Last year, Boris Ratnikov was reading a paper and saw a familiar image.

He quickly realized: The image was from a 2012 paper he’d written, but wasn’t cited. The 2016 Cell Metabolism paper he was reading had copied a figure from his 2012 PLOS ONE paper without referencing it. 

In September 2016, Ratnikov, who is based at Sanford-Burnham-Prebys Medical Discovery Institute, in La Jolla, California, emailed an editor at Cell Metabolism to express his concern about the duplication and omitted citation.  

Although the journal told us it “carefully investigated Dr Ratnikov’s concerns,” the editors ultimately did not think the literature needs correcting.

Does failing to cite a paper constitute plagiarism? Continue reading When is a citation not enough?

Ketamine-depression paper retracted following investigation at Yale

A psychiatry journal has retracted a 2011 paper exploring the use of ketamine to treat patients with severe depression following an investigation at Yale University.

According to the retraction notice, Yale determined that the paper, published in the International Journal of Neuropsychopharmacology, did not accurately describe the research. But the study’s lead author, Gregory Larkin, says he believes the retraction “is wholly unnecessary, serving neither patients nor science.”

Continue reading Ketamine-depression paper retracted following investigation at Yale